Matthew Ros - 16 Aug 2021 Form 4 Insider Report for Epizyme, Inc.

Role
Executive Vice President, Chief Strategy & Business Officer
Signature
/s/ John Weidenbruch, attorney-in-fact
Issuer symbol
N/A
Transactions as of
16 Aug 2021
Net transactions value
$0
Form type
4
Filing time
18 Aug 2021, 08:02:56 UTC
Previous filing
06 Jul 2021
Next filing
05 Oct 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EPZM Common Stock, par value $0.0001 Award $0 +28,125 +34% $0.000000 111,313 16 Aug 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EPZM Stock Option (Right to Buy) Award $0 +134,178 $0.000000 134,178 16 Aug 2021 Common Stock 134,178 $5.31 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of shares of Common Stock issuable under 28,125 restricted stock units ("RSUs") granted pursuant to the Company's 2013 Stock Incentive Plan. Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in three equal annual installments over three years from the grant date, with the first installment vesting on August 16, 2022.
F2 This option was granted on August 16, 2021 pursuant to the Company's 2013 Stock Incentive Plan with respect to 134,178 shares of Common Stock, with 33.33% vesting on August 16, 2022 and the remaining 66.67% vesting in 24 substantially equal monthly installments thereafter.

Remarks:

Executive Vice President, Chief Strategy & Business Officer